Lv51
990 积分 2023-12-13 加入
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
5小时前
待确认
Navigating the Evolving Landscape of EGFR -Mutated NSCLC
5小时前
待确认
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
4天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
7天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
8天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant【更正版，谢谢】
8天前
已关闭
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
8天前
已完结
Virus‐like particles as powerful vaccination strategy against human viruses
9天前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
10天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
11天前
已完结
皖公网安备34019202002308
